BURBANK, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) — by way of NewMediaWire – Medolife Rx, Inc. (“Medolife”), a world built-in biopharmaceutical firm with R&D, manufacturing, and client product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), introduced right this moment outcomes from a research on its patented polarization methodology that in contrast the effectiveness of generic ibuprofen, a well known ache aid drug that works by decreasing irritation by inhibiting the cyclooxygenase-2 (COX-2) enzyme’s exercise within the physique, versus polarized ibuprofen in inhibition of COX-2 exercise in people. The outcomes confirmed that polarized ibuprofen was 257% simpler in inhibiting COX-2, which is expressed in irritation and ache in people. The outcome additional solidifies the potential functions of polarization on the healthcare trade as a complete, whereas the therapeutic efficacy of energetic pharmaceutical substances (APIs) will be elevated via the method, and dosage will be decreased, leading to fewer unintended effects and potential injury to the liver.
The research befell on the Pasadena Bio Collaborative Incubator, utilizing a COX-2 assay from Cayman Chemical Firm. The assay offered a fluorescent base for screening human recombinant COX-2 and the research was carried out with black flat backside 96-well plates with outcomes measured on Spectramax ID3 multi-mode microplate readers. The experiment checked out COX-2 inhibition when three completely different types of ibuprofen have been launched: one non-polarized, one destructive polarized, and one polarized. The outcomes, as proven in Determine 1.1, confirmed a rise of COX-2 inhibition within the polarized pattern when in comparison with the non-polarized pattern, the place the inhibition was 257.67% greater than the non-polarized pattern of ibuprofen.
“Past all the things else we’re doing, on the core of our firm’s worth stays the potential for the usage of the polarization expertise throughout the healthcare spectrum,” stated Medolife CEO Dr. Arthur Mikaelian. “Via this check we validated but once more how properly polarization works in rising the efficacy of APIs. A 257% improve in efficacy is actually a scientific breakthrough for the medical group. Whereas ibuprofen is seemingly innocent on the physique at low doses, it has led to abdomen bleeding and different critical unintended effects with continued use. That is the case with many main pharmaceutical medicine. A number of the world’s handiest medicines may cause vital unintended effects and injury to the interior physique. If we have been in a position to introduce polarization to a few of these, we may lower the dose mandatory to attain the specified impact, in flip lowering this potential injury and related unintended effects. This might apply to medicine similar to chemotherapy, which is well-known for its adversarial unintended effects, but is utilized in a big proportion of most cancers therapies. We need to companion with massive pharmaceutical firms similar to AstraZeneca and Pfizer, amongst others who produce chemotherapy medicine, with a purpose to introduce them to polarization. Via our course of we may improve the efficacy of chemo whereas lowering the dose required, assuaging the unintended effects of that drug for hundreds if not tens of millions of sufferers. The functions for this expertise are actually limitless and we’ve confirmed as soon as once more that it really works with virtually any API.”
Whereas the Firm continues to pursue regulatory approval on its pharmaceutical product Escozine®, it’s actively searching for further research and collaborations with main pharmaceutical firms to discover how polarization may very well be used to extend the efficacy of a few of the world’s main medicine.
About Medolife Rx
Medolife Rx, Inc. is a world biotechnology firm with operations in medical analysis, manufacturing, and client merchandise. Medolife Rx was created via the merger of Medolife, a personal firm based by Dr. Arthur Mikaelian who pioneered the unlaying polarization expertise that makes the Firm’s portfolio of pharmaceutical and nutraceutical merchandise so efficient, and Quanta, Inc., a direct-to-consumer wellness product portfolio firm. The Firm’s lead medical improvement applications embody Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions which is amplified by the Firm’s polarization expertise and is being researched as a remedy of assorted indications, together with COVID-19 and most cancers. The Firm has accomplished preclinical security and efficacy analysis on Escozine® and is pursuing product registration and drug approval in varied international locations, together with the US and all through Latin America.
Via its subsidiary QuantRx, Medolife manufactures and distributes client wellness and nutraceutical merchandise in high-impact client areas similar to ache aid, magnificence, and normal wellness. QuantRx merchandise are designed utilizing Dr. Mikaelian’s polarization expertise which applies advances in quantum biology to extend the efficiency of energetic substances. At the moment, QuantRx helps product formulations in ache administration, anti-inflammation, skincare, agriculture, dietary dietary supplements, and plant-based consumables. In the end, Quanta’s mission is to ship higher, simpler substances to raise product efficacy, cut back waste, and facilitate more healthy, extra sustainable consumption.
Past its personal medical and client functions, the polarization expertise utilized by Medolife and its subsidiaries has many potential functions. From potentiating bio-ingredients, to producing more-effective carbon-trapping vegetation, to transformative anti-aging options, Medolife has the chance to upend how industrial and pharmaceutical merchandise are made and improve their advantages, whereas reducing their chemical focus.
Protected Harbor Assertion beneath the U.S. Personal Securities Litigation Reform Act of 1995: This launch incorporates statements which can be forward-looking in nature which specific the beliefs and expectations of administration together with statements concerning the Firm’s anticipated outcomes of operations or liquidity; statements regarding projections, predictions, expectations, estimates or forecasts as to our enterprise, monetary and operational outcomes and future financial efficiency; and statements of administration’s objectives and goals and different related expressions regarding issues that aren’t historic info. In some instances, you may establish forward-looking statements by terminology similar to “anticipate,” “estimate,” “plan,” “undertaking,” “persevering with,” “ongoing,” “anticipate,” “we consider,” “we intend,” “could,” “will,” “ought to,” “may,” and related expressions. Such statements are primarily based on present plans, estimates and expectations and contain quite a lot of recognized and unknown dangers, uncertainties and different components that would trigger the Firm’s future outcomes, efficiency or achievements to vary considerably from the outcomes, efficiency or achievements expressed or implied by such forward-looking statements. These components and extra info are mentioned within the Firm’s filings with the Securities and Alternate Fee and statements on this launch must be evaluated in gentle of those necessary components. Though we consider that these statements are primarily based upon affordable assumptions, we can’t assure future outcomes. Ahead-looking statements converse solely as of the date on which they’re made, and the Firm undertakes no obligation to replace publicly or revise any forward-looking assertion, whether or not because of new info, future developments or in any other case.